RESEARCH · BPC-157 + TB-500 · GI MUCOSAL
BPC-157, Gastrointestinal Mucosa and Cytoprotection: Gut Injury Models and How Thymosin β4 Compares
BPC-157 (GEPPPGKPADDAGLV; molecular weight 1419) is a stable gastric pentadecapeptide studied mainly in rodent gastrointestinal injury models and described as stable in human gastric juice [1,2]. Our earlier articles cover the preclinical picture and human-data gap and molecular mechanisms involving NO, VEGFR2 and FAK/ILK. This article focuses on mucosal cytoprotection and gut injury: alcohol and NSAID lesion models, perforation and fistula healing, anastomoses and short-bowel work, and how published thymosin β4 (Tβ4 / TB-500-class) gut evidence compares. PurixLab’s BPC-157 + TB-500 10mg is a research blend (BPC-157 5mg + TB-500 5mg, 1:1 in one vial) for laboratory research use only.
Cytoprotection as the organising idea
Reviews from the Sikiric group place BPC-157 inside Robert’s cytoprotection and adaptive cytoprotection framework: mucosal defence against necrotising irritants that is not explained by acid suppression alone, with proposed translation from stomach epithelium and endothelium to broader organoprotection [3,4]. Early NO-system work showed that BPC-157 protected against ethanol-induced gastric lesions and interacted with L-NAME and L-arginine effects on mucosa and blood pressure in a pattern distinct from L-arginine alone [5]. Contemporary reviews still frame BPC-157 as a candidate cytoprotection mediator, while noting that clinical translation beyond early inflammatory-bowel-disease trial codes (PL-10, PLD-116, PL 14736) remains limited [1,4].
NSAID, alcohol and recurrent ulcer models
In rats, BPC-157 reduced gastrointestinal lesions induced by indomethacin, aspirin and diclofenac and also attenuated adjuvant arthritis over long observation windows [6]. In a diclofenac toxicity model spanning stomach, intestine, liver and encephalopathy, BPC-157 antagonised the combined lesion pattern when given intraperitoneally or in drinking water [7]. After healing of acetic-acid ulcers, clopidogrel promoted ulcer recurrence with endoplasmic-reticulum-stress apoptosis and suppressed angiogenesis markers; BPC-157 attenuated that recurrence and reversed molecular changes involving VEGF-A/VEGFR1 and AKT/p38 MAPK signalling, with L-NAME weakening the protection [8]. Alcohol models remain central: Gojkovic and colleagues redefined Robert’s intragastric 96% alcohol challenge as an escalated peripheral and central syndrome (gastric lesions plus intracranial hypertension, brain swelling, portal/caval hypertension and multi-organ injury) that BPC-157 counteracted when given shortly after alcohol [9].
Perforation, fistulas, anastomoses and short bowel
Surgically perforated stomach in rats produces vascular failure, bleeding and defect widening; BPC-157 applied as an abdominal bath rapidly restored vessel presentation toward the defect, reduced bleeding and supported later healing, with early transcript changes in Cox2, VEGFa and NOS isoforms [10]. Stomach perforation has also been characterised as a general occlusion/occlusion-like syndrome with intracranial and portal hypertension; BPC-157 into the perforated defect contracted the stomach and attenuated brain, heart, lung and visceral lesions [11]. Duodenocolic fistula creation (two perforated lesions joined) closed under BPC-157 regimens with simultaneous vessel recruitment on duodenal and colonic sides and loss of fistula leakage, unlike persistent defects, diarrhoea and weight loss in controls [12]. A 2024 review summarises healing of many distinctive intestinal anastomoses and both external and internal fistulas under BPC-157 in rats [13]. In escalating short-bowel syndrome after massive small-bowel resection, BPC-157 was associated with constant weight gain above preoperative values and increased villus height, crypt depth and inner circular muscle thickness over 4 weeks [14].
Thymosin β4 (TB-500-class) gut evidence: a mixed picture
Recombinant human Tβ4 improved survival, reduced epithelial injury and inflammatory cytokines, and attenuated intestinal fibrosis in DSS colitis models, with transcriptomic evidence for suppressed mineralocorticoid-receptor (NR3C2) signalling; TMSB4X was downregulated in colonic tissues of IBD patients, and Tmsb4x-deficient mice were more susceptible to DSS colitis [15]. By contrast, other groups report that upregulated Tβ4 can impair the mucus barrier by inhibiting autophagy in DSS colitis [16], and that mast-cell–derived Tβ4 under stress impairs epithelial barrier function via IL22RA1/JAK1/STAT3 signalling in irritable-bowel-syndrome-related models, with high Tβ4 in IBS mucus [17]. In chronic granulomatous disease models, Tβ4 promoted noncanonical autophagy and mucosal-barrier gene programmes via HIF-1α stabilisation and reduced colitis severity [18]. Relative to BPC-157’s large, mostly single-laboratory cytoprotection literature, Tβ4 gut papers are fewer, more recent and directionally inconsistent across barrier versus repair endpoints.
What remains open
- Human mucosal data are thin. IBD trial codes are cited repeatedly, but modern controlled human mucosal-healing datasets for BPC-157 are scarce [1,4].
- Laboratory concentration. Much of the cytoprotection corpus comes from one extended research network [2,4].
- Tβ4 is not a simple parallel. Barrier-impairing and barrier-repairing findings coexist [15,16,17].
- Blend pharmacology is untested. Co-formulated BPC-157 and TB-500 have no published combined gut-injury trial; each peptide’s literature must be read separately.
BPC-157 + TB-500 10mg at PurixLab
BPC-157 + TB-500 10mg: a labelled lyophilized research vial with BPC-157 5mg + TB-500 5mg (1:1) per vial, C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-21. PubMed 17186181 · doi:10.1007/s10787-006-1531-7
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PubMed 21548867 · doi:10.2174/138161211796196954
- Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Curr Pharm Des. 2010;16(10):1224-34. PubMed 20166993 · doi:10.2174/138161210790945977
- Sikiric P, Sever M, Krezic I, et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. 2024;32(5):3119-3161. PubMed 38980576 · doi:10.1007/s10787-024-01499-8
- Sikirić P, Seiwerth S, Grabarević Z, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol. 1997;332(1):23-33. PubMed 9298922 · doi:10.1016/s0014-2999(97)01033-9
- Sikiric P, Seiwerth S, Grabarevic Z, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris. 1997;91(3-5):113-22. PubMed 9403784 · doi:10.1016/s0928-4257(97)89474-0
- Ilic S, Drmic D, Franjic S, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci. 2011;88(11-12):535-42. PubMed 21295044 · doi:10.1016/j.lfs.2011.01.015
- Wu H, Wei M, Li N, et al. Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157. Drug Des Devel Ther. 2020;14:5599-5610. PubMed 33376304 · PMC7763470 · doi:10.2147/DDDT.S284163
- Gojkovic S, Krezic I, Vranes H, et al. Robert's Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157. Biomedicines. 2021;9(10):1300. PubMed 34680419 · PMC8533388 · doi:10.3390/biomedicines9101300
- Bilic Z, Gojkovic S, Kalogjera L, et al. Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide pentadecapeptide BPC 157 in rats with perforated stomach throughout modulation of nitric oxide-system. Comparison with L-arginine, ranitidine and pantoprazole therapy and L-NG-nitro-L-arginine methyl ester worsening. J Physiol Pharmacol. 2021;72(6). PubMed 35485358 · doi:10.26402/jpp.2021.6.11
- Kalogjera L, Krezic I, Smoday IM, et al. Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect. World J Gastroenterol. 2023;29(27):4289-4316. PubMed 37545637 · PMC10401663 · doi:10.3748/wjg.v29.i27.4289
- Vukusic D, Zenko Sever A, Sever M, et al. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. J Physiol Pharmacol. 2024;75(1). PubMed 38583442 · doi:10.26402/jpp.2024.1.09
- Bajramagic S, Sever M, Rasic F, et al. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel). 2024;17(8):1081. PubMed 39204186 · PMC11357423 · doi:10.3390/ph17081081
- Sever M, Klicek R, Radic B, et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci. 2009;54(10):2070-83. PubMed 19093208 · doi:10.1007/s10620-008-0598-y
- Zhao TR, Hu EB, Wang MW, et al. Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling. Mol Biomed. 2026;7(1):140. PubMed 42606759 · PMC13481925 · doi:10.1186/s43556-026-00539-9
- Hao M, Zhong K, Bai X, et al. Upregulated Tβ4 expression in inflammatory bowel disease impairs the intestinal mucus barrier by inhibiting autophagy in mice. Exp Cell Res. 2024;434(1):113871. PubMed 38049080 · doi:10.1016/j.yexcr.2023.113871
- Sun YS, Bai XQ, Sun KD, et al. Thymosin β4 released by mast cells under stress conditions impairs intestinal epithelial barrier via IL22RA1/JAK1/STAT3 signaling in irritable bowel syndrome. World J Gastroenterol. 2025;31(42):111706. PubMed 41278163 · PMC12635723 · doi:10.3748/wjg.v31.i42.111706
- Renga G, Oikonomou V, Moretti S, et al. Thymosin β4 promotes autophagy and repair via HIF-1α stabilization in chronic granulomatous disease. Life Sci Alliance. 2019;2(6):e201900432. PubMed 31719116 · PMC6851533 · doi:10.26508/lsa.201900432